{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:41:53Z","timestamp":1790379713408,"version":"4.1.0"},"reference-count":33,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2022,1,7]]},"DOI":"10.1253\/circrep.cr-21-0140","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T22:07:44Z","timestamp":1637014064000},"page":"1-8","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor"],"prefix":"10.1253","volume":"4","author":[{"given":"Tetsufumi","family":"Motokawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Atomic Bomb Disease and Hibakusya Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Maemura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. <i>N Engl J Med<\/i> 2006; 355: 2408\u20132417.","DOI":"10.1056\/NEJMoa062867"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood<\/i> 2012; 119: 1123\u20131129.","DOI":"10.1182\/blood-2011-08-376087"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. <i>J Clin Oncol<\/i> 2016; 34: 2333\u20132340.","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: A subanalysis of the DASISION 5-year final report. <i>Int J Hematol<\/i> 2017; 105: 792\u2013804.","DOI":"10.1007\/s12185-017-2208-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, et al. Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era. <i>Leuk Res<\/i> 2010; 34: 1459\u20131471.","DOI":"10.1016\/j.leukres.2010.03.033"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. <i>Blood<\/i> 2011; 118: 4554\u20134560.","DOI":"10.1182\/blood-2011-04-347575"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. <i>N Engl J Med<\/i> 1971; 285: 1441\u20131446.","DOI":"10.1056\/NEJM197112232852601"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chuah CT, Nakamae H, Shen ZX, Bradley-Garelik MB, Kim DW. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase. <i>Leuk Lymphoma<\/i> 2014; 55: 2093\u20132100.","DOI":"10.3109\/10428194.2013.866663"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hjorth-Hansen H, Stenke L, Soderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006). <i>Eur J Haematol<\/i> 2015; 94: 243\u2013250.","DOI":"10.1111\/ejh.12423"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. <i>Blood<\/i> 2007; 110: 1233\u20131237.","DOI":"10.1182\/blood-2007-01-070144"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Estabragh ZR, Knight K, Watmough SJ, Lane S, Vinjamuri S, Hart G, et al. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. <i>Leuk Res<\/i> 2011; 35: 49\u201351.","DOI":"10.1016\/j.leukres.2010.08.020"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Izumi-Nakaseko H, Fujiyoshi M, Hagiwara-Nagasawa M, Goto A, Chiba K, Kambayashi R, et al. Dasatinib can impair left ventricular mechanical function but may lack proarrhythmic effect: A proposal of non-clinical guidance for predicting clinical cardiovascular adverse events of tyrosine kinase inhibitors. <i>Cardiovasc Toxicol<\/i> 2020; 20: 58\u201370.","DOI":"10.1007\/s12012-019-09538-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, Lapeyre-Mestre M, et al. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: An approach combining pharmacovigilance and pharmacodynamics. <i>Br J Clin Pharmacol<\/i> 2017; 83: 1544\u20131555.","DOI":"10.1111\/bcp.13238"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ikeda S, Koga S, Yamagata Y, Koide Y, Kawano H, Mukae H, et al. Pulmonary thromboembolism caused by calcification in the inferior vena cava of a Japanese adult. <i>Intern Med<\/i> 2019; 58: 1907\u20131912.","DOI":"10.2169\/internalmedicine.2259-18"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqu\u00e9 C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood<\/i> 2014; 123: 494\u2013500.","DOI":"10.1182\/blood-2013-06-511592"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cortes JE, Jean Khoury H, Kantarjian H, Br\u00fcmmendorf TH, Mauro MJ, Matczak E, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. <i>Am J Hematol<\/i> 2016; 91: 606\u2013616.","DOI":"10.1002\/ajh.24360"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. <i>Leuk Res<\/i> 2011; 35: 626\u2013630.","DOI":"10.1016\/j.leukres.2010.10.017"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Weatherald J, Chaumais MC, Savale L, Jais X, Seferian A, Canuet M, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: A population-based study. <i>Eur Respir J<\/i> 2017; 50: 1700217.","DOI":"10.1183\/13993003.00217-2017"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Quintas-Cardama A, Kantarjian H, O\u2019Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. <i>J Clin Oncol<\/i> 2007; 25: 3908\u20133914.","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. <i>Br J Haematol<\/i> 2008; 141: 745\u2013747.","DOI":"10.1111\/j.1365-2141.2008.07108.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: A case series. <i>Am J Respir Crit Care Med<\/i> 2007; 176: 814\u2013818.","DOI":"10.1164\/rccm.200705-715CR"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. <i>Bone Marrow Transplant<\/i> 2009; 43: 967\u2013968.","DOI":"10.1038\/bmt.2008.415"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Montani D, Bergot E, G\u00fcnther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. <i>Circulation<\/i> 2012; 125: 2128\u20132137.","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. <i>Eur Respir J<\/i> 2019; 53: 1801913.","DOI":"10.1183\/13993003.01913-2018"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ryan JJ. Tyrosine kinase inhibitors in pulmonary vascular disease. <i>JACC Basic Transl Sci<\/i> 2016; 1: 684\u2013686.","DOI":"10.1016\/j.jacbts.2016.11.005"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Nagaraj C, Tang B, B\u00e1lint Z, Wygrecka M, Hrzenjak A, Kwapiszewska G, et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. <i>Eur Respir J<\/i> 2013; 41: 85\u201395.","DOI":"10.1183\/09031936.00211811"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Damrongwatanasuk R, Fradley MG. Cardiovascular complications of targeted therapies for chronic myeloid leukemia. <i>Curr Treat Options Cardiovasc Med<\/i> 2017; 19: 24.","DOI":"10.1007\/s11936-017-0524-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. <i>Int J Cancer<\/i> 2020; 147: 3160\u20133167.","DOI":"10.1002\/ijc.33119"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Porta-S\u00e1nchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: A systematic review. <i>J Am Heart Assoc<\/i> 2017; 6: e007724.","DOI":"10.1161\/JAHA.117.007724"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. <i>N Engl J Med<\/i> 2002; 347: 472\u2013480.","DOI":"10.1056\/NEJMoa020461"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Thanopoulou E, Judson I. The safety profile of imatinib in CML and GIST: Long-term considerations. <i>Arch Toxicol<\/i> 2012; 86: 1\u201312.","DOI":"10.1007\/s00204-011-0729-7"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica<\/i> 2011; 96: 1457\u20131461.","DOI":"10.3324\/haematol.2011.041251"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Zhuang W, Xie JD, Zhou S, Zhou ZW, Zhou Y, Sun XW, et al. Can therapeutic drug monitoring increase the safety of imatinib in GIST patients? <i>Cancer Med<\/i> 2018; 7: 317\u2013324.","DOI":"10.1002\/cam4.1286"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/4\/1\/4_CR-21-0140\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T03:28:45Z","timestamp":1641612525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/4\/1\/4_CR-21-0140\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-21-0140","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"article-number":"CR-21-0140"}}